The fact that the increase in Covid cases and the emergence of a novel variety coincided with widespread immunization appears far too coincidental.

It’s still unclear whether this novel Covid Delta Variant was caused by “shedding.”

However, as the FDA acknowledged in 2015, it is worth investigating and appears to be extremely likely.

Documents from the FDA from 2015 have surfaced, revealing that they were aware of “vaccines” and virus shedding.

Despite this, we’ve seen “health officials” claim that shedding is a hoax throughout the pandemic.

The documents on shedding advise scientists on what should be included in “shedding research.”

The word “shedding” is defined by the FDA as “the release of VBGT or oncolytic products from the patient by one or more of the following mechanisms: excreta (feces); secreta (urine, saliva, nasopharyngeal secretions, etc. ); or skin (pustules, sores, wounds).”

The following is an excerpt from the full study on shedding:

The Center for Biologics Evaluation and Research (CBER)/Office of Cellular, Tissue, and Gene Therapies (OCTGT) is issuing this guidance to provide you, sponsors of virus or bacteria-based gene therapy products (VBGT products)1 and oncolytic viruses or bacteria (oncolytic products)2 with recommendations on how to conduct shedding studies during preclinical and clinical development. For purposes of this guidance, the term “shedding” means release of VBGT or oncolytic products from the patient through one or all of the following ways: excreta (feces); secreta (urine, saliva, nasopharyngeal fluids etc.); or through the skin (pustules, sores, wounds). Shedding is distinct from biodistribution because the latter describes how a product is spread within the patient’s body from the site of administration while the former describes how it is excreted or released from the patient’s body. Shedding raises the possibility of transmission of VBGT or oncolytic products3 from treated to untreated individuals (e.g., close contacts and health care professionals). This guidance represents FDA’s current thinking on how and when shedding data should be collected for VBGT and oncolytic products during preclinical and clinical development and how shedding data can be used to assess the potential for transmission to untreated individuals. This guidance finalizes the draft guidance of the same title dated July 2014. FDA’s guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the FDA’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in FDA’s guidances means that something is suggested or recommended, but not required’


VBGT and oncolytic products are derived from infectious viruses or bacteria. In general, these products are not as infectious or as virulent as the parent strain of virus or bacterium because of, in part, the derivation methods and/or modifications made during product development that lead to attenuation. Hence, it is likely that these products are shed to a lesser extent than during natural infection by the parent strain. Nonetheless, the possibility that the shed VBGT or oncolytic product may be infectious raises safety concerns related to the risk of transmission to untreated individuals. To understand this risk, shedding studies that are conducted in the target patient population(s) may be appropriate before licensure. Typically, clinical shedding studies are not stand-alone studies but are integrated into the design of a safety or efficacy trial. Because there are many product-specific factors and patient-specific factors that can influence the design of a shedding study, sponsors should consult with OCTGT in the early stages of product development for specific recommendations as to their product.


Shedding studies should be conducted for each VBGT or oncolytic product to provide information about the likelihood of transmission to untreated individuals because historical data alone may not be predictive of the shedding profile. Shedding data can be used to evaluate measures to prevent transmission. Shedding data collected during product development should provide a clear and comprehensive understanding of the shedding profile of VBGT or oncolytic products in the target patient population(s). Note that it may be appropriate to describe these data in the package insert for an approved Biologics License Application (BLA). To inform the design of human shedding studies, shedding data may be collected in animals following administration of the VBGT or oncolytic product. These data can help estimate the likelihood and potential shedding profile in humans, particularly when there is concern about transmission to untreated individuals. However, such data cannot substitute for human shedding studies for several reasons. For example, a VBGT or oncolytic product may be derived from a human-specific strain; therefore, animals may not adequately predict the shedding profile in humans. Similarly, various animal species/models may not adequately address patient-specific factors, such as differences in the immune status at the time of product administration, which may contribute to the potential for shedding in humans (for more details refer to section VII.B. of this guidance).

Dividing and/or auxotrophic bacteria; auxotrophic bacteria are unable to synthesize an organic molecule required for their growth and division but when this molecule is available with the other nutrients they require, growth and division of the bacteria may occur. • Introduced into the human body through unnatural routes and hence, the infectivity, replication, persistence and shedding from the human body may be different than that of the parental strains. • Engineered to carry transgenes, e.g., tropism-altering genes, immune modifying gene(s) or genes that enhance oncolysis.


There is strength in unity and America is a great example of it to the countries across the world. In the need of the hour, each patriot has sacrificed their needs to help out a fellow citizen.

However, hope can be lost in the darkest times, and the American people need something to unify them in such times of adversity. The fight is not over yet, says President Trump.

This coin is a medium through which all citizens can be reminded that there is light at the end of the tunnel and America under the competent leadership of Donald Trump, there is no challenge America cannot overcome.

President Trump’s victory coin is unsurprisingly on course to become the most popular Presidential coin in the history of our great country, and the liberals just can’t deal with this.

The President is now calling on his loyal supporters to aid him in the battle against the dangerous democrat party. He needs all of us to show our support for the movement that is making America great again.

So he’s giving away a limited number of his exclusive victory coin for FREE, but not for long.

As you can imagine, these coins are hot property and it’s impossible to know how many are left. So you need to act fast.

Click here to claim the Donald Trump Victory Coin.

You too can own a unique piece of history when you act now.

If you want to help the cause against the democrats and show your support for our country, what better way to do that than with President Trump’s Victory coin?


This article contains commentary which reflects the author’s opinion
Admin News

Leave a Reply

Your email address will not be published. Required fields are marked *